title: Pilot study of ifosfamide/carboplatin/etoposide (ICE) for peripheral blood stem cell mobilization in patients with high-risk or relapsed medulloblastoma.
abstract: OBJECTIVE
  The purpose of this study is to evaluate the stem cell mobilization capacity, anti-tumor effect, and feasibility of ifosfamide/carboplatin/etoposide (ICE) for transplant-eligible patients with medulloblastoma.
  
  
  METHODS
  Six patients (23 months to 18 years old) with high-risk or relapsed medulloblastoma received one cycle of ICE, which consisted of ifosfamide at 1.8 g/m(2) for 5 days, carboplatin 400 mg/m(2) for 2 days, and etoposide 100 mg/m(2) for 5 days. Stem cells were mobilized with ICE followed by granulocyte colony-stimulating factor at 10 microg kg(-1) day(-1).
  
  
  RESULTS
  After one cycle of ICE, the median number of harvested CD34+ cells per apheresis session was 11.85 x 10(6) cells/kg (range, 0.2 to 71.2 x 10(6) cells/kg). Two patients obtained a complete response and three patients a partial response. All patients experienced severe myelosuppression, and three infectious toxicities were observed.
  
  
  CONCLUSIONS
  These results suggest that ICE is optimal for mobilizing stem cells, effective for high-risk or relapsed medulloblastoma, and tolerable with limited non-hematological toxicity.
authors.affiliation: Department of Pediatrics, Hamamatsu University School of Medicine, Handayama 1-20-1, Hamamatsu, Japan. sokada@hama-med.ac.jp
authors.forename: Shuichi
authors.initials: S
authors.lastname: Okada
authors.forename: Teruaki
authors.initials: T
authors.lastname: Hongo
authors.forename: Kimiyoshi
authors.initials: K
authors.lastname: Sakaguchi
authors.forename: Kazunori
authors.initials: K
authors.lastname: Suzuki
authors.forename: Shigeru
authors.initials: S
authors.lastname: Nishizawa
authors.forename: Takehiko
authors.initials: T
authors.lastname: Ohzeki
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D007223:Infant; D008297:Male; D008527:Medulloblastoma / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation; D016879:Salvage Therapy
chemical_list: D000970:Antineoplastic Agents; D016179:Granulocyte Colony-Stimulating Factor; D005047:Etoposide; D016190:Carboplatin; D007069:Ifosfamide